Not So Different: A Podcast From The Center For Biosimilars

Opinion: Impact of Inflation Reduction Act 2022—Addressing Critics https://www.centerforbiosimilars.com/view/opinion-impact-of-inflation-reduction-act-2022-addressing-critics Opinion: The Inflation Reduction Act is a Step Backward for Biosimilar Competition https://www.centerforbiosimilars.com/view/opinion-the-inflation-reduction-act-is-a-step-backward-for-biosimilar-competition $35 Insulin Cap for Private Sector Blocked From Budget Reconciliation Bill https://www.centerforbiosimilars.com/view/-35-insulin-cap-for-private-sector-blocked-from-budget-reconciliation-bill European Commission Approves Second Lucentis Biosimilar https://www.centerforbiosimilars.com/view/european-commission-approves-second-lucentis-biosimilar FDA Approves Coherus’ Cimerli as Interchangeable Biosimilar to Ranibizumab https://www.centerforbiosimilars.com/view/fda-approves-coherus-cimerli-as-interchangeable-biosimilar-to-ranibizumab FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar https://www.